Lusvertikimab (anti-IL-7R) has shown promising results in phase II trials for ulcerative colitis, while HuMax-IL15 (anti-IL-15) has demonstrated tolerability and efficacy in early-phase RA trials 127. This evidence concerns the gene IL15 and rheumatoid arthritis.